论文部分内容阅读
AIM:To determine whether serum interleukin-18 (IL-18) levels correlated with clinicopathologic features and prognosis in patients with hepatocellular carcinoma (HCC). METHODS:Serum IL-18,IL-6 and IL-12 levels were measured by enzyme-linked immunosorbent assay (ELISA) from 70 patients with HCC and 10 healthy controls. RESULTS:Serum IL-18,IL-6 and IL-12 levels of patients with HCC were significantly higher that those of the controls. The levels of IL-18 correlated significantly with the presence of venous invasion and advanced tumor stages classified by Okuda’s criteria. Patients with high serum IL-18 levels (≥ 105 pg/mL) had a poorer survival than those with low serum IL-18 levels (< 105 pg/mL) (4 and 11 mo,respectively,P = 0.015). Multivariate analyses showed that serum IL-18 level,but not IL-6 and IL-12 levels,was a significant and independent prognostic factor of survival. CONCLUSION:These findings demonstrate that serum IL-8 may a useful biological marker of tumor invasiveness and an independent prognostic factor of survival for patients with HCC. Thus,the detailed mechanisms of IL-18 involving in tumor progression should be further investigated.
AIM: To determine whether serum interleukin-18 levels correlated with clinicopathologic features and prognosis in patients with hepatocellular carcinoma (HCC). METHODS: Serum IL-18, IL-6 and IL-12 levels were measured by enzyme- linked immunosorbent assay (ELISA) from 70 patients with HCC and 10 healthy controls. RESULTS: Serum IL-18, IL-6 and IL-12 levels of patients with HCC were significantly higher those those of the controls. The levels of IL- 18 Patients with high serum IL-18 levels (≥ 105 pg / mL) had a poorer survival than those with low serum IL-18 levels (<105 pg / Multivariate analyzes showed that serum IL-18 level, but not IL-6 and IL-12 levels, was a significant and independent prognostic factor of survival. CONCLUSION: These findings demonstrate that serum IL-8 may a useful biological marker of tumor invasiveness and an independent prognostic factor of survival for patients with HCC. Thus, the detailed mechanisms of IL-18 involving in tumor progression should be further investigated.